Introduction
Paliperidone, marketed under the brand name Invega, is an atypical antipsychotic medication that has gained significant attention in the field of psychiatry. It is the primary active metabolite of risperidone, another well-known antipsychotic drug. This article aims to provide a comprehensive overview of the clinical pharmacological research on paliperidone, covering its mechanism of action, pharmacokinetics, efficacy, safety, and clinical applications.
Product Code: BM-2-5-122
English Name: Paliperidone/invega
CAS No.: 144598-75-4
Molecular formula: C23H27FN4O3
Molecular weight: 426.48
EINECS No.: 620-493-1
MDL No.：MFCD00871802
Hs code: 29349990
Analysis items: HPLC>99.0%, LC-MS
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Changzhou Factory
Technology service: R&D Dept.-4
We provide Paliperidone Powder CAS 144598-75-4, please refer to the following website for detailed specifications and product information.
Mechanism of Action
Paliperidone, like other atypical antipsychotics, exerts its therapeutic effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors. However, its precise mechanism of action in treating schizophrenia and other psychiatric disorders remains incompletely understood. It is proposed that the drug's therapeutic activity is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. For instance, its antagonism of α2 adrenergic receptors may contribute to its efficacy in improving depressive symptoms, as blocking these receptors can enhance the release of norepinephrine and serotonin in the brain.
In vitro studies have shown that the pharmacological activity of the (+)- and (-)-paliperidone enantiomers is qualitatively and quantitatively similar. This suggests that both enantiomers contribute to the overall therapeutic effect of the drug.
|
|
|
Pharmacokinetics
Absorption
Paliperidone is available in both oral extended-release (ER) tablet form and as a long-acting injectable suspension (paliperidone palmitate). The oral ER tablet uses the osmotic-controlled release oral delivery system (OROS), which allows for the gradual release of the drug over a 24-hour period. This results in relatively smooth diurnal plasma paliperidone concentrations with low peak-to-trough fluctuations at steady state.
Following oral administration, the maximum plasma concentration (Cmax) of paliperidone is reached approximately 24 hours after dosing. The absorption of paliperidone is enhanced when the drug is taken with food, with an increase in absorption rate of about 60%.
Distribution
Paliperidone has a large volume of distribution, estimated to be around 487 liters. It is highly bound to plasma proteins, with a plasma protein binding rate of 74%. This high protein binding suggests that paliperidone is less likely to be affected by drug interactions involving protein displacement.
Metabolism and Elimination
Paliperidone is primarily eliminated unchanged in the urine, with approximately 59% of the administered dose excreted as the parent compound. The remainder is metabolized, primarily through non-enzymatic pathways, and excreted in the urine and feces.
In vitro studies have indicated that paliperidone is a substrate for CYP2D6 and CYP3A4 enzymes. However, in vivo studies have not supported a clinically significant role for these enzymes in the metabolism of paliperidone. This suggests that paliperidone is less prone to drug interactions involving CYP enzymes compared to other antipsychotics.
The terminal half-life of paliperidone is approximately 23 hours, allowing for once-daily dosing. The long-acting injectable form of paliperidone (paliperidone palmitate) has a more prolonged release profile, with therapeutic concentrations maintained for up to one month after a single injection.
Efficacy
Paliperidone has been extensively studied for its efficacy in treating schizophrenia. Clinical trials have demonstrated its effectiveness in reducing both positive and negative symptoms of schizophrenia, as well as improving cognitive function and social functioning.
Acute Treatment
Several randomized, double-blind, placebo-controlled trials have evaluated the efficacy of paliperidone in the acute treatment of schizophrenia. These studies have consistently shown that paliperidone is superior to placebo in reducing symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS).
For example, in a 6-week study involving 628 patients with schizophrenia, Kane et al. found that paliperidone at doses of 6, 9, and 12 mg/day was significantly more effective than placebo in reducing PANSS total scores. Similar results were observed in other studies, with paliperidone showing efficacy at doses ranging from 3 to 15 mg/day.
Maintenance Treatment
Paliperidone has also been studied for its efficacy in the maintenance treatment of schizophrenia. In a long-term study involving 205 patients, Kramer et al. found that paliperidone was significantly more effective than placebo in preventing relapse. The median time to relapse was significantly longer in the paliperidone group compared to the placebo group.
Other Indications
In addition to schizophrenia, paliperidone has been studied for its efficacy in treating schizoaffective disorder. It has been shown to be effective as monotherapy or as an adjunct to mood stabilizers and/or antidepressants in the treatment of this condition.
|
|
|
Safety and Tolerability
Paliperidone is generally well-tolerated, with a safety profile similar to other atypical antipsychotics. However, like all medications, it is associated with certain adverse effects.
Common Adverse Effects
The most common adverse effects of paliperidone include:
- Extrapyramidal Symptoms (EPS): These include akathisia, dystonia, parkinsonism, and tardive dyskinesia. The incidence of EPS with paliperidone is generally lower than with typical antipsychotics but may still occur, particularly at higher doses.
- Weight Gain: Weight gain is a common side effect of paliperidone, with some studies reporting an average weight gain of 2-3 kg over 6-12 months of treatment.
- Sedation and Somnolence: Patients may experience drowsiness or fatigue, particularly during the initial phases of treatment.
- Orthostatic Hypotension: Paliperidone can cause a drop in blood pressure upon standing, leading to dizziness or fainting.
- Prolactin Elevation: Paliperidone can increase prolactin levels, which may lead to symptoms such as galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction.
Serious Adverse Effects
Although rare, paliperidone has been associated with serious adverse effects, including:
- Neuroleptic Malignant Syndrome (NMS): A potentially life-threatening condition characterized by fever, muscle rigidity, autonomic instability, and altered mental status.
- QT Prolongation: Paliperidone can prolong the QT interval, which may increase the risk of ventricular arrhythmias. Patients with a history of QT prolongation, heart failure, or other cardiac conditions should be monitored closely.
- Tardive Dyskinesia (TD): A potentially irreversible movement disorder characterized by involuntary, repetitive movements. The risk of TD increases with long-term use of antipsychotics.
Drug Interactions
Paliperidone is less prone to drug interactions compared to other antipsychotics due to its minimal metabolism by CYP enzymes. However, it is still important to monitor for potential interactions, particularly with drugs that prolong the QT interval or affect the central nervous system.
Dosing and Administration
The recommended starting dose of paliperidone for the treatment of schizophrenia is 6 mg once daily. The dose can be titrated upwards in increments of 3 mg/day at intervals of no less than 5 days, with a maximum recommended dose of 12 mg/day.
For patients switching from risperidone to paliperidone, the initial dose of paliperidone should be based on the patient's previous risperidone dose. Generally, a 1:1 dose conversion is recommended, although individual patient response may vary.
The long-acting injectable form of paliperidone (paliperidone palmitate) is administered once monthly. The initial dosing regimen involves two injections: 234 mg on day 1 and 156 mg on day 8. Subsequent monthly maintenance doses range from 39 mg to 234 mg, depending on the patient's response and tolerability.
Special Populations
Elderly Patients
Elderly patients may be more sensitive to the adverse effects of paliperidone, particularly EPS, orthostatic hypotension, and sedation. Lower initial doses and slower titration may be necessary in this population.
Pediatric Patients
The safety and efficacy of paliperidone in pediatric patients have not been established. However, it has been studied in adolescents aged 12-17 years with schizophrenia, with results suggesting that it is generally well-tolerated and effective in this age group.
Patients with Renal or Hepatic Impairment
Patients with renal or hepatic impairment may require dose adjustments due to altered drug metabolism and elimination. For patients with mild to moderate renal impairment, no dose adjustment is generally necessary. However, for patients with severe renal impairment, the maximum recommended dose is 6 mg/day. For patients with hepatic impairment, no dose adjustment is recommended for mild to moderate impairment, but caution should be exercised in patients with severe impairment.
Conclusion
Paliperidone is an effective and generally well-tolerated atypical antipsychotic medication that has been shown to be effective in the treatment of schizophrenia and schizoaffective disorder. Its unique pharmacokinetic properties, including gradual release and minimal metabolism by CYP enzymes, make it a valuable option for patients who may be at risk for drug interactions or who require a more stable plasma concentration profile.
However, like all medications, paliperidone is associated with certain adverse effects, and patients should be monitored closely for signs of EPS, weight gain, sedation, orthostatic hypotension, and prolactin elevation. Additionally, the risk of serious adverse effects such as NMS and QT prolongation should be considered, particularly in patients with pre-existing cardiac conditions.
Overall, paliperidone represents an important addition to the armamentarium of treatments for schizophrenia and other psychiatric disorders. Its efficacy, safety profile, and convenient dosing options make it a valuable option for both acute and maintenance treatment.